Article Text

Download PDFPDF
The death of administrative data for benchmarking cardiothoracic mortality?
  1. D Pagano1,2,
  2. C P Gale3,4
  1. 1Clinical Director Quality and Outcome Research Unit, University Hospital Birmingham, Birmingham, UK
  2. 2School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, UK
  3. 3Division of Epidemiology and Biostatistics, Leeds Institute of Genetics Health and Therapeutics, University of Leeds, Leeds, UK
  4. 4Department of Cardiology, York Teaching Hospital NHS Foundation Trust, York, UK
  1. Correspondence to Dr Chris P Gale, Division of Epidemiology and Biostatistics, University of Leeds, Level 8, Worsley building, Clarendon Way, West Yorkshire, Leeds LS2 9JT, UK; c.p.gale{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The decision to recommend surgical treatment for patients with cardiac surgical disease is based on a multidisciplinary approach of the evaluation of the intended benefits and inherent risks of the proposed treatment.1 This is particularly important for patients of advancing age, with multiple comorbidities and who receive complex interventions. Such patients have higher operative risk and, increasingly, form the routine referral base for cardiothoracic operations. Subjective assessment of a patient's clinical risk, undertaken in isolation, is no longer acceptable—objective evaluation is highly recommended, allowing patients and surgeons a more informed decision and commissioners, regulators and researchers a mechanism to benchmark standards of access to and outcomes of care.2

It is, therefore, essential that reliable and valid tools are established which predict outcomes after surgery. Higher risk may then be quantified and, where appropriate, patients offered alternative evidence-based therapies. This is relevant to coronary artery and aortic valve disease interventions where, in parallel with established cardiothoracic operations provider volume-outcome associations are under close scrutiny and some cardiac devices may, in future, be ‘commissioned through evaluation’. Specifically, between and within centre surgical outcomes are regularly monitored and compared, as part of institutional, national and international quality improvement programmes.2 ,3 Thus, case-mix adjustment that carefully models the full spectrum of baseline patient risk is central to the identification of ‘outlier’ status and the evaluation of the quality of care of operative interventions.4

Siregar et al5 use clinical and administrative data from the majority of hospitals in The Netherlands performing cardiac surgery to report the differences in data quality and model performance indices with and without model recalibration. Clinical data are sourced from their National Cardiac Surgical Registry, analogous to the UK Society for Cardiothoracic Surgery (SCTS) in Great Britain and Ireland registry, and administrative data from the …

View Full Text


  • Contributors CPG and DP drafted, reviewed, amended and approved the manuscript.

  • Funding National Institute for Health Research.

  • Competing interests CPG is funded by the National Institute for Health Research (NIHR/CS/009/004) as a Clinician Scientist and Honorary Consultant Cardiologist.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles